Cargando…

Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have proven cardiovascular benefits, are recommended in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). However, there is limited real-world evidence comparing the effects of once-weekly (O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Xi, Liang, Yuanjie, Rajpura, Jigar R., Yedigarova, Larisa, Noone, Josh, Xie, Lin, Inzucchi, Silvio, de Havenon, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662529/ https://www.ncbi.nlm.nih.gov/pubmed/37985992 http://dx.doi.org/10.1186/s12933-023-02051-8

Ejemplares similares

Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series
por: Lajthia, Estela, et al.
Publicado: (2019)

Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes
por: Kawasaki, Eiji, et al.
Publicado: (2021)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
por: Mousa, Shaker A., et al.
Publicado: (2019)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen
por: Suzuki, Katsunori, et al.
Publicado: (2018)

Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
por: Avogaro, Angelo, et al.
Publicado: (2014)

A Review on Cardiovascular Outcome Studies of Dipeptidyl Peptidase-4 Inhibitors
por: Khalse, Maneesha, et al.
Publicado: (2018)

3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy
por: El Sanadi, Caroline E., et al.
Publicado: (2020)

Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
por: Dawwas, Ghadeer K., et al.
Publicado: (2018)

Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men
por: Tsuchiya, Saori, et al.
Publicado: (2016)

Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease
por: Baksh, Sheriza N., et al.
Publicado: (2020)

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
por: Nauck, M.
Publicado: (2016)

Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
por: Thotamgari, Sahith Reddy, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
por: Foresta, Andreana, et al.
Publicado: (2023)

The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients
por: Huang, Chun-Feng, et al.
Publicado: (2023)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
por: Santamarina, Marile, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
por: Krishna, Rajesh, et al.
Publicado: (2016)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Goldman, Jennifer D.
Publicado: (2020)

Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
por: Michel, Martin C., et al.
Publicado: (2008)

The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
por: Yousefzadeh, Pegah, et al.
Publicado: (2013)

Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease
por: Zhong, Jixin, et al.
Publicado: (2015)

Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
por: Ha, Kyoung Hwa, et al.
Publicado: (2018)

Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
por: Chen, Jia-Jin, et al.
Publicado: (2022)

Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes
por: Tong, Yan, et al.
Publicado: (2023)

Efficacy and safety of once‐weekly oral trelagliptin switched from once‐daily dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: An open‐label, phase 3 exploratory study
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

A theoretical investigation on the geometries of glucagon-like peptide-1 and its interactions with dipeptidyl peptidase DPP-IV
por: Brickmann, Jürgen, et al.
Publicado: (2008)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
por: Zhou, Xiaoyan, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study
por: Baksh, Sheriza, et al.
Publicado: (2021)

A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes
por: Gantz, Ira, et al.
Publicado: (2017)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitor (Vildagliptin) Improves Glycemic Control After Meal Tolerance Test by Suppressing Glucagon Release
por: Okamoto, Aki, et al.
Publicado: (2014)

Dipeptidyl‐Peptidase 4 Inhibition and the Vascular Effects of Glucagon‐like Peptide‐1 and Brain Natriuretic Peptide in the Human Forearm
por: Devin, Jessica K., et al.
Publicado: (2014)

Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension
por: Wang, Jingjing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tubvuihvh3ppkqbqu7bb5ba3mk